Equities

Gelteq Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GELS:NAQ

Gelteq Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.795
  • Today's Change0.030 / 3.96%
  • Shares traded1.35k
  • 1 Year change-64.03%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

  • Revenue in USD (TTM)117.10k
  • Net income in USD-4.70m
  • Incorporated2017
  • Employees7.00
  • Location
    Gelteq LtdLevel 4, 100 Albert RoadMELBOURNE 3205AustraliaAUS
  • Phone+61 39087-3990
  • Websitehttps://www.gelteq.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LakeShore Biopharma Co Ltd89.02m-14.47m5.33m573.00--0.03710.8010.0599-0.749-0.7494.653.480.4270.50011.30155,360.70-6.94---15.95--82.47---16.26--0.7452-2.630.453--7.24--76.93------
Sunshine Biopharma Inc37.32m-5.99m5.74m52.00--0.2204--0.1538-2.03-2.0310.745.311.212.0910.12717,764.30-19.47-68.65-23.80-89.0233.0132.79-16.06-81.122.09-209.950.00--44.75340.11-13.94--370.33--
cbdMD Inc19.19m-4.38m7.36m42.00--0.8655--0.3835-3.92-3.924.770.81041.832.8318.96---19.44-48.27-44.42-54.9962.3763.95-10.63-85.601.20--0.00---1.50-14.4543.21---32.56--
Tian'an Pharmaceutical Co Ltd10.65m3.14m8.00m--0.04450.00972.200.75110.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Gelteq Ltd117.10k-4.70m8.51m7.00--0.7618--72.68-0.4977-0.49770.01241.040.0078--0.515516,728.25-31.47-17.38-40.60-19.16-----4,011.74-4,507.46---3.520.2106-------87.40------
Biofrontera Inc37.17m-17.57m9.07m92.00------0.2441-1.84-1.844.07-0.22162.192.449.45403,967.40-103.57-48.03-339.69-77.5564.4148.93-47.28-60.990.8033-47.482.37--9.547.3511.78---35.51--
Cuprina Holdings (Cayman) Ltd24.03k-2.24m9.22m14.00--1.52--383.54-0.1234-0.12340.00130.28350.004913.390.79761,716.66-44.56---131.50---69.27---9,194.46--3.58-306.250.0244---52.05---39.39------
Integrated Biopharma Inc53.43m672.00k9.31m153.0014.140.45439.400.17420.02120.02121.710.65972.074.4512.77349,183.002.609.983.2813.689.7510.741.264.581.92--0.0072--8.020.5933482.30-30.67-0.8556--
CV Sciences Inc14.37m-1.48m9.37m47.00--6.09--0.6525-0.008-0.0080.0780.00841.871.6734.74305,659.60-19.21-44.92-66.32-105.3247.0442.89-10.29-49.080.2125-2.020.3829---1.87-21.80-177.18---56.43--
Lotus Pharmaceuticals Inc70.79m1.72m9.52m233.000.06510.0012.470.13450.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Bon Natural Life Ltd18.67m-1.99m10.12m96.0018.630.2316--0.54180.0880.0886.747.080.25416.071.64194,486.40-2.795.82-3.977.8620.7728.53-10.9810.831.61-4.440.17350.00-21.700.4899-577.58--18.20--
Nexgel Inc11.67m-2.88m10.59m19.00--2.04--0.9075-0.3796-0.37961.530.63691.053.7913.46613,947.40-25.14-39.08-36.83-49.7938.3019.60-23.91-105.401.08-51.360.1439--112.4764.69-3.93------
Akari Therapeutics PLC (ADR)0.00-15.77m10.67m8.00---------0.600-0.6000.00--0.00----0.00-65.57-112.46-136.47-257.78-----------27.770.0854-------97.75------
Data as of Feb 13 2026. Currency figures normalised to Gelteq Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.72%Per cent of shares held by top holders
HolderShares% Held
G1 Execution Services LLCas of 30 Sep 202541.55k0.39%
Wedbush Securities, Inc. (Investment Management)as of 31 Dec 202520.00k0.19%
Virtu Americas LLCas of 30 Sep 202515.47k0.14%
Raymond James Financial Services Advisors, Inc.as of 30 Sep 20250.000.00%
HRT Financial LPas of 31 Dec 20250.000.00%
Morgan Stanley & Co. LLCas of 31 Dec 20250.000.00%
UBS Securities LLCas of 31 Dec 20250.000.00%
Citadel Securities LLCas of 30 Sep 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.